Abuse Liability and Human Pharmacology of Mephedrone
Brief Summary
The purposes of this study are 1) to evaluate the abuse liability and human pharmacology of mephedrone after oral administration and 2) to compare the pharmacological effects of mephedrone with those obtained after administration of oral 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).
Condition or Disease
- Amphetamine-Related Disorders
Phase
Study Design
| Study type: | Interventional |
|---|---|
| Status: | Completed |
| Study results: | No Results Available |
| Age: | 18 Years to 45 Years (Adult) |
| Enrollment: | 12 () |
| Funded by: | Other |
Masking |
|
Clinical Trial Dates
| Start date: | Sep 01, 2014 | |
|---|---|---|
| Primary Completion: | Dec 01, 2014 | |
| Completion Date: | Dec 01, 2014 | |
| Study First Posted: | Sep 05, 2014 | |
| Results First Posted: | Aug 30, 2020 | |
| Last Updated: | Dec 04, 2014 |
Sponsors / Collaborators
Lead Sponsor:
N/A
Responsible Party:
N/A
Location
Mephedrone is a new psychoactive substance (NPS). At present, there are no randomized controlled trials evaluating the effects of mephedrone in humans. The current body of knowledge regarding the acute effects of mephedrone is based on anecdotal, self-reported effects (e.g. internet forums), case reports, and emergency room series and fatalities.
The aims of this study are 1) to evaluate the abuse liability and human pharmacology of mephedrone after oral administration and 2) to compare the pharmacological effects of mephedrone with those obtained after administration of oral 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).
Eligibility Criteria
| Sex: | Male |
|---|---|
| Minimum Age: | 18 |
| Maximum Age: | 45 |
More Details
| NCT Number: | NCT02232789 |
|---|---|
| Other IDs: | IMIMFTCL/MEF/1 |
| Study URL: | https://ClinicalTrials.gov/show/NCT02232789 |
Last updated: Jun 16, 2022